» Articles » PMID: 19562292

The Burden of Chronic Obstructive Pulmonary Disease in Patients Hospitalized with Heart Failure

Overview
Publisher Springer
Specialty General Medicine
Date 2009 Jun 30
PMID 19562292
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Like chronic heart failure, chronic obstructive pulmonary disease (COPD) is an enormous public health problem in industrialized countries. Our aim was to determine the prevalence and clinical impact of COPD among patients hospitalized for heart failure in a community hospital serving a population of 125,000 people.

Methods: Between 2001 and 2003 a total of 638 patients (73 +/- 10 years, 48% men, 74% NYHA class III) were identified with a discharge diagnosis of heart failure. Medical charts were reviewed and vital status was obtained from a Central Population Registry.

Results: COPD was diagnosed in 106 (17%) patients whose age was similar to those without COPD (73 +/- 9 vs. 73 +/- 11 years, P = 0.35). Patients with COPD were more often males (65% vs. 45%, P < 0.001). There were no differences in arterial hypertension, atrial fibrillation, diabetes mellitus and most laboratory markers except hemoglobin (141 +/- 20 vs. 132 +/- 20 g/l, P < 0.001) and uric acid (453 +/- 136 vs. 414 +/- 139 mmol/l, P = 0.013). At discharge, patients with COPD were less likely to receive beta-blockers (12% vs. 28%, odds ratio 0.35, 95% CI0.19-0.64). During follow-up, patients with COPD had higher mortality (73% vs. 60%, P = 0.016, hazard ratio 1.48, 95% CI 1.15-1.90). Kaplan-Meier (log-rank test, P = 0.002) and Cox proportional hazard analysis, adjusted for age, sex, hemoglobin, uric acid, and treatment with beta-blockers and furosemide (hazard ratio 1.38, 95% CI1.04-1.83, P = 0.024) demonstrated the prognostic importance of COPD.

Conclusions: COPD is frequent among hospitalized patients with heart failure. Beta-blockers are largely underused, which is probably a major reason for the higher mortality observed in patients with concomitant chronic heart failure and COPD.

Citing Articles

The Saudi Thoracic Society Evidence-based guidelines for the diagnosis and management of chronic obstructive pulmonary disease.

Al-Jahdali H, Al-Lehebi R, Lababidi H, Alhejaili F, Habis Y, Alsowayan W Ann Thorac Med. 2025; 20(1):1-35.

PMID: 39926399 PMC: 11804957. DOI: 10.4103/atm.atm_155_24.


Serum Uric Acid and Risk of Chronic Heart Failure: A Systematic Review and Meta-Analysis.

Miao L, Guo M, Pan D, Chen P, Chen Z, Gao J Front Med (Lausanne). 2022; 8:785327.

PMID: 34977088 PMC: 8715937. DOI: 10.3389/fmed.2021.785327.


Heart failure among US nursing home residents with diabetes mellitus.

Osundolire S, Naqvi S, Nunes A, Lapane K Int J Cardiol. 2021; 349:138-143.

PMID: 34826498 PMC: 8766946. DOI: 10.1016/j.ijcard.2021.11.035.


PRIME-HF: Novel Exercise for Older Patients with Heart Failure. A Pilot Randomized Controlled Study.

Giuliano C, Levinger I, Vogrin S, Neil C, Allen J J Am Geriatr Soc. 2020; 68(9):1954-1961.

PMID: 32293033 PMC: 7540058. DOI: 10.1111/jgs.16428.


Association of Medication Intensity and Stages of Airflow Limitation With the Risk of Hospitalization or Death in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease.

Lawson C, Mamas M, Jones P, Teece L, McCann G, Khunti K JAMA Netw Open. 2019; 1(8):e185489.

PMID: 30646293 PMC: 6324325. DOI: 10.1001/jamanetworkopen.2018.5489.


References
1.
Macchia A, Monte S, Romero M, DEttorre A, Tognoni G . The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. Eur J Heart Fail. 2007; 9(9):942-8. DOI: 10.1016/j.ejheart.2007.06.004. View

2.
von Haehling S, Lainscak M, Springer J, Anker S . Cardiac cachexia: a systematic overview. Pharmacol Ther. 2008; 121(3):227-52. DOI: 10.1016/j.pharmthera.2008.09.009. View

3.
Lainscak M, Andreas S, Scanlon P, Somers V, Anker S . Ghrelin and neurohumoral antagonists in the treatment of cachexia associated with cardiopulmonary disease. Intern Med. 2006; 45(13):837. DOI: 10.2169/internalmedicine.45.1867. View

4.
Rabe K, Hurd S, Anzueto A, Barnes P, Buist S, Calverley P . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007; 176(6):532-55. DOI: 10.1164/rccm.200703-456SO. View

5.
Staszewsky L, Wong M, Masson S, Barlera S, Carretta E, Maggioni A . Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. J Card Fail. 2007; 13(10):797-804. DOI: 10.1016/j.cardfail.2007.07.012. View